Lenalidomide and Paclitaxel in Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00933426
Recruitment Status : Terminated (Terminated early due to slow accrual as Phase I dose escalation study.)
First Posted : July 7, 2009
Last Update Posted : October 26, 2016
Celgene Corporation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : December 2015
  Actual Study Completion Date : December 2015